Conditions & Recovery · Cancer Health — Science · June 2, 2026

Teclistamab Extends Survival, Deepens Remissions in Relapsed Multiple Myeloma

Findings published in NEJM and presented at ASCO 2026 show the bispecific immunotherapy significantly outperformed standard treatments.

Originally published by Cancer Health — Science. We curate and add context; they did the reporting.

Related learning